Possible complications

DIFFERENCES BETWEEN SURGICAL AND MEDICAL TECHNIQUES:

ATTACHED INFORMATION

FLASGO (Latin American Federation of Gynaecology and Obstetrics Societies), published these indications.

The following table compares the schemes based on evidence in France and at the FDA.

French schemes

EU: FDA Scheme

Evidence-based Scheme
Dose of MIFEPRISTONE 600 mg (Day 1) 600 mg (Day 1) 200 mg (Day 1)
Dose of MISOPROSTOL 400 µg, PO (alternative) 1mg gemeprost, PV) 400 µg, PO 400 µg, PO or 800 µg, PV
Gestational limit < 49 days < 49 days < 63 days
Administration of MISOPROSTOL Medical Consultancy / Clinic Medical Consultancy / Clinic Medical Consultancy / Clinic
Date on which MISOPROSTOL is administered Day 2 or 3 Day 3 Day 2, 3 or 4
Date of check-up Day 10 to 14 Day 14 Day 4 to 14
Number of clinical consultations Three or more Three or more Two or more

Regardless of the scheme chosen, there are various steps that should be followed to achieve an abortion with medication using MIFEPRISTONE-MISOPPROSTOL.

MIFEPRISTONE is recommended for the following indications:

1) For the medical interruption of a pregnancy:

  • Up to a maximum of 63 days after the first day of your last menstrual period,
  • In combination with another treatment (prostaglandin, a substance which increases the contraction of the uterus) which is taken 36 to 48 hours after taking MIFEPRISTONE.

2) To soften and dilate the neck of the uterus prior to the surgical interruption of a pregnancy during the first trimester.

3) As a treatment prior to the administration of prostaglandins for the interruption of pregnancy for medical reasons after the 3rd month of gestation.

4) To induce a birth in cases where the foetus has died in the uterus and when the use of other medical treatments (prostaglandins or oxytocinergic) is not possible.

See related subjects